03 January 2025
03 January 2025
Though still below boom levels seen a few years ago, 2024 compares favourably to 2023, and signs suggest that growth will continue into 2025.
The Phase III KOASTAL-1 study with Neumora’s lead asset navacaprant failed to meet its primary and secondary endpoint.
Novo Nordisk’s Wegovy made a significant impact on the obesity market when it launched in 2021.
The approval of sotatercept came through the International Recognition Procedure.
HUTCHMED is set to gain a milestone payment from AstraZeneca.
The approval is underpinned by data from 15 clinical trials involving 800 healthy volunteers.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
